Mays Cancer Center at UT Health SA

项目摘要-实验和发展治疗(EDT)计划 实验和发展治疗(EDT)计划是三个互动研究计划之一 德克萨斯大学圣安东尼奥分校梅斯癌症中心(MCC)。安德鲁 Brenner医学博士和Manjeet Rao博士担任EDT项目的联合负责人。的主要关注点 EDT计划旨在通过基础研究、转化研究和临床研究来改善癌症的治疗。美国东部夏令时 该计划是MCC所有成员发现的临床开发的中心。EDT计划 成员拥有横跨实验和发育疗法的专业知识--从最初的靶标发现， 到IND监管部门批准，到早期临床试验。EDT计划成员继续进行这项研究 聚焦于三个主要主题：1)神经肿瘤学；2)免疫肿瘤学；3)药物再利用。此外 对于这些主要主题，EDT计划有一个新兴的主题：靶向治疗。EDT成员将 通过以下具体目标提高这些主题的翻译潜力：1)发现 新的靶点；2)开发新的治疗药物和方法；以及3)进行早期临床 新疗法的试验。EDT计划目前有36名成员，代表三个部门中的13个部门 德克萨斯大学健康学院(医学、牙科和研究生)。两名成员来自德克萨斯大学 奥斯汀和德克萨斯州立大学的一名成员。15名成员领导临床试验。EDT计划 成员拥有570万美元的同行评议的癌症相关资金(27笔赠款)。其中，270万美元来自15家NCI 资助金。从2014年1月到2019年6月，EDT计划成员共同撰写了414篇与癌症相关的同行评议 出版物中，24%来自计划内协作，16%来自计划间协作 合作。此外，79%的出版物涉及多机构合作，其中包括192项 (46%)与NCI指定的其他癌症中心合作的出版物。EDT成员使用所有MCC支持的 共享资源，以继续其交叉研究，特别是马萨诸塞州的生物统计学和生物信息学 光谱分析、药物发现和结构生物学设施。EDT成员还领导了130项干预 临床试验，仅在2018年，就有226名患者参加了干预试验。

Project Summary—Experimental and Developmental Therapeutics (EDT) Program The Experimental and Developmental Therapeutics (EDT) Program is one of three interactive research programs of the Mays Cancer Center (MCC) at the University of Texas Health San Antonio (UT Health SA). Andrew Brenner, M.D., Ph.D. and Manjeet Rao, Ph.D. serve as Co-Leaders of the EDT Program. The primary focus of the EDT Program is to improve treatment of cancer through basic, translational, and clinical research. The EDT Program is the hub for clinical development of discoveries made by all members of MCC. The EDT Program members have expertise spanning experimental and developmental therapeutics – from initial target discovery, to IND regulatory approval, to early-phase clinical trials. The EDT Program members pursue this research focused on three major themes: 1) Neuro-oncology; 2) Immuno-oncology; and 3) Drug repurposing. In addition to these major themes, the EDT Program has one emerging theme: Targeted therapeutics. EDT members will advance the translational potential within these themes through the following Specific Aims: 1) Discovery of novel targets; 2) Development of new therapeutic agents and approaches; and 3) Conduct of early-phase clinical trials of novel therapies. The EDT Program currently has 36 members, representing 13 departments within three schools (Medical, Dental and Graduate) at UT Health SA. Two members are from the University of Texas at Austin and one member from Texas State University. Fifteen members lead clinical trials. The EDT Program members have $5.7M of peer-reviewed cancer-related funding (27 grants). Of those, $2.7M are from 15 NCI grants. From January 2014 to June 2019, EDT Program members coauthored 414 peer-reviewed cancer-related publications, 24% were from intra-programmatic collaborations and 16% were from inter-programmatic collaborations. In addition, 79% of these publications involve multi-institutional collaborations, including 192 (46%) publications with other NCI-designated Cancer Centers. EDT members use all of the MCC-supported Shared Resources to pursue their cross-cutting research, especially the Biostatistics and Bioinformatics, Mass Spectrometry, Drug Discovery and Structural Biology facilities. EDT members have also led 130 interventional clinical trials, and in 2018 alone, 226 patients were accrued to intervention trials.